Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

IBRX fits the immuno-oncology theme through Anktiva, its approved therapy that boosts key cancer-fighting immune cells.

Genomics & Biotechnology ETF (GNOM) declares a semi-annual distribution of $0.057900 Payable Jul 07; for shareholders of record Jun 29; ex-div Jun 29. More on Global X Genomics & Biotechnology ETF ...

Biotech ETFs are surging in 2026 as a friendlier FDA, strong M&A activity and AI-driven drug discovery fuel optimism for more ...

XBI has “moved higher a record 12 of 13 months,” Mizuho healthcare sector specialist Jared Holz wrote Friday.

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

From broad domestic exposure to global pharma and biotech, these funds cover the healthcare sector's main themes.

IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...

The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: XBI), which tracks the biotech portion of the S&P 500, started in January ...